PRESENTATION

FY2024 — Results presentation

FY2024PDF · 75 pages5.4 MB
Annual Results
Presentation
for the year ended 30 June 2024

-- 1 of 75 --

2
Normalised
operating profit
Core new
business
+18%
to R26 667m
+17%
to R11 604m
Normalised
headline earnings
+15%
to R7 329m
Headline
earnings
+7%
to R7 202m
Total income from
non-insurance
+16%
to R6 191m
FY24 performance overview
Excluding discontinued products
like VitalityInvest and DBI and Ping
An Health reinsurance business
Discovery Insure	
Discovery Life	
Discovery Invest	
Discovery Bank	
Discovery Health
Vitality Limited
Vitality Health	
Vitality Life	
Vitality Network	
Vitality Health	
International

-- 2 of 75 --

3
Slow but steady economic recovery
Moderate GDP growth Slowing inflation Outlook	High interest rates
Inflation rate by market1 Central bank policy rates2
1 Sources: StatsSA, Statista, Office for National Statistics, US Bureau of Labor Statistics
2 Source: Bank of International Settlements
Global
• Declining global inflation
• Accommodative financial conditions
• Stable growth expected
• Geopolitical tensions persist with elections in
major economies
South Africa
• Stabilising interest rates
• Moderating inflation; consumer pressure remains
• Economic green shoots post-GNU
United Kingdom
• NHS challenges persist
• Modest growth; falling inflation continues
• Recovering consumer spending
China
• Strained West relations
• GDP growth expected to reach 5% in 2024
• Stabilising exports from global manufacturing
recovery
• Accommodative policy expected
United States
• Recession fears due to slowing growth and
cooling jobs market
• Falling inflation; Fed commenced cutting rates
• Elevated geopolitical risk from volatile politics
0%
1%
2%
3%
4%
5%
6%
7%
8%
9%
Jan-20	
Jul-20	
Jan-21	
Jul-21
Jan-22	
Jul-22	
Jan-23	
Jul-23	
Jan-24	
Jul-24
South Africa
United Kingdom
China
United States
-2%
0%
2%
4%
6%
8%
10%
12%
Jun-20	
Dec-20	
Jun-21	
Dec-21	
Jun-22	
Dec-22	
Jun-23	
Dec-23	
Jun-24
United States
South Africa
China
United Kingdom
0%
1%
2%
3%
4%
5%
6%
7%
8%
9%
2021	
2022	
2023	
2024f	
2025f
World
United Sates
Euro area
China
South Africa

-- 3 of 75 --

4
Focus areas
Entering a new phase in the lifecycle of the Group
1
2
3
Strong FY24 performance
Delivering on business-specific performance
Creating two distinct businesses with significant ambition
and a common business model
4

-- 4 of 75 --

5
FY24 Performance

-- 5 of 75 --

6
Strong operating performance
Health 3 972 +7% 11 069 +26% 1 260 +5%
Life 4 765 +9% 2 942 +4%
Invest 1 522 +20% 3 300 +8%
Insure 248 +240% 1 388 +11%
Bank -454 -41% 2 102 +39%
Other SA1 -336 +20% 1 038 +38%
SA 9 717 +16% 19 737 +19% 3 362 +24%
Vitality Health 435 -47% 2 488 +21%
Vitality Life 375 -20% 1 956 +14%
UK initiatives -163 -70%
UK 647 -14% 4 444 +17%
Vitality Network 533 +30% 1 894 +16%
VHI - Ping An Health 1 124 +85% 2 486 +14% 935 -6%
VHI - Other -386 +98%
VG initiatives -31 -11%
VG 1 240 +57% 2 486 +14% 2 829 +8%
Operating profit New business2
1 Vitality, Other SA Initiatives and Group initiatives and central costs 2 Excl products in run down
Non-insurance
incomeZARm
+17%
R11 604m +18%
R26 667m +16%
R6 191m

-- 6 of 75 --

7
40%
50%
60%
70%
80%
FY19 FY20 FY21 FY22 FY23 FY24
12%
14%
16%
18%
20%
22%
24%
26%
28%
30%
FY22 FY23 FY24
0% CSM 50% CSM 100% CSM
Group well capitalised with robust cash generation
FLR decreasing Strongly capitalised Improving cash conversion
Sufficient centre
liquidity
DHMS solvency
(unaudited) 30%
1 Capital Adequacy Ratio
2 Comprehensive Solvency Ratio, definition set by China Banking and Insurance Regulatory Commission
3 Centre cash + undrawn committed facilities
4 Normalised for COVID-19 reserve impact
28%
23%
20%
17%
FLR
Jun 23
Cover
Jun 24
Cover
Life 1.8x 1.8x
Insure 1.6x 1.6x
VH 1.4x 1.6x
VL 2.1x 2.0x
Bank1 1.3x 1.3x
PAHI2 2.7x 3.2x
Group cash conversion4	Centre liquidity3, Rm
66%
-
500
1,000
1,500
2,000
2,500
3,000
3,500
4,000
4,500
R4.1bn
(R1.5bn of which to be used
to repay maturing debt by
Nov 2024)

-- 7 of 75 --

8
Strong growth in Group Embedded Value
Opening EV Value of new
business
Unwind of risk
discount rate
Non-economic
experience
variances and
methodology &
assumption
changes
Operational EV Economic
experience
variances and
methodology &
assumption
changes
Non-Covered
Businesses
Forex Finance Costs,
Investment
Income & Other
Change in
Captial &
Dividends
Closing EV
R113 439m
R98 176m
R110 354m
13.2%
Annualised RoEV

-- 8 of 75 --

9
Below the line affected by swaption in prior period
Rm 12 months
ended
12 months
ended
%	Jun-24 Jun-23
Normalised profit from operations 11 604 9 917 17%
Forex losses/gains -87 150
1 DP financing lease impact -105 -134
Investment income and fair value gains on financial instruments 480 354
Finance charges excl. 1DP finance lease -1 750 -1 628
Other -131 -117
Profit before fair value gains on VL swaption 10 011 8 543 17%
Fair value gains on VL swaption 516
Profit before tax 10 011 9 059 11%
Tax -2 647 -2 486
Profit not attributable to ordinary shareholders -206 -174
Loss on impairment and derecognition 48 257
Other headline earnings adjustments -4 65
Headline earnings 7 202 6 720 7%
Fair value gains on VL swaption 0 -410
Other 127 90
Normalised headline earnings 7 329 6 400 15%
Fair value gains: prior period includes a
considerable fair value gain from the swaption
held in DHEL, which was realised towards the
end of the previous financial year
Forex losses/gains: ZAR closing rates
strengthened compared to opening rates
resulting in losses on translation of GBP and USD
currency accounts and loans receivable. In the
prior year, the closing rates weakened resulting in
a foreign translation gain
Loss on impairment and derecognition: Largely
attributable to write-off of assets resulting from
wind-down of VitalityCar and assets no longer in
use in VitalityHealth
Final dividend declaration of
152cps in respect of FY24

-- 9 of 75 --

10
Entering a new phase of growth
Past Today Future
Highly cash generative with superior
growth. Maintaining leadership in SA
with the Bank scaling; and a
material international business
Pioneering and globalising the
Vitality shared-value model;
substantial investment in new
initiatives for organic growth
Reduced spend and streamlined
new initiatives; key initiatives
maturing; transitioned to IFRS 17

-- 10 of 75 --

11
The new phase of growth should have a positive impact on
financial metrics
Average
Where we
were
(FY16-FY23)
Where we are
today
(FY24)
Where we are
headed
(FY25-FY29)
Earnings growth 9%
CAGR 17% 15-20%
CAGR
% spend on New 15%
(maxed at 25%) 8% c5%
Cash conversion 56% 66% 60-70%
RoE 13% 13% 15-20%
FLR 22% 20% 10-20%
Dividend cover 5.7x 5x <5x
Forward looking information on this slide is for illustration and has not been reviewed or reported on by the auditors

-- 11 of 75 --

12
Strong operating profit performance
Operating profit, Rm
-
2,000
4,000
6,000
8,000
10,000
12,000
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
IFRS 17	IFRS 4
COVID-19

-- 12 of 75 --

13
Three distinct phases
Operating profit by phase of growth, Rm
-
2,000
4,000
6,000
8,000
10,000
12,000
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Big investments
in New
Unfettered organic
growth
CAGR
9.1%
CAGR
22.3% 15-20%
p.a.
Scaled organic
growth
(FY25-FY29)
Forward looking information on this slide is for illustration and has not been reviewed or reported on by the auditors

-- 13 of 75 --

14
Growth dynamics of the operating and business model
Organic growth engine Vitality shared-value business model
Upfront
selection Persistency Claims
Consistent value drivers across the business yielding superior outcomes
relative to traditional insurance books
LIFE
HEALTH
INSURE
Profitability
17%
Claims savings
from initial
selection
7%
Claims
reduction from
initial selection
23%
Good drivers
self-selecting
42%
Lower lapses
20%
Lower lapses
64%
Lower lapses
9%
Claims reduction
13%
Claims reduction
58%
Claim severity
reduction
Community-
rated and not
for profit
12%
Higher VNB
margin
17%
Lower loss
ratios
Profitability
ESTABLISHED	EMERGING	NEW
CPI + 5%	CPI + 30%	-10%
Aim for Group
to be on the
growth curve

-- 14 of 75 --

15
Entering a new phase of growth
% spend
on new
Dividend
cover
Cash
conversion
(normalised
history)
Operating
profit
growth
FLR
RoE
Going forward: scaled organic growth
15-20%
RoE
15-20%
CAGR
c5%
Spend on new
10-20%
FLR
<5x
Dividend cover
60-70%
Cash conversion
-20%
0%
20%
40%
0%
10%
20%
30%
0%
10%
20%
30%
0%
50%
0
0.2
0.4
-
2
4
6
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
Big investments in New	Unfettered organic growth
Illustrative ranges
Average 13%	Average 20%
Average 22%
Average
3%
4.6x 5.7x
CAGR
IFRS 4
9%	CAGR 22%
8% 15%
56%	60%
Average
Average
Average
Average
Average
Average
13%
20%
5x
17%
8%
66%
Forward looking information on this slide is for illustration and has not been reviewed or reported on by the auditors and reflects the average expected over the time frame
R14.5bn in the Bank

-- 15 of 75 --

16
The new phase should result in an improving central cash position
Forward looking information on this slide is for illustration and has not been reviewed or reported on by the auditors
Improving cash
conversion
Cash conversion
Reducing demand for cash from the centre
Cash from the centre, Rm
Vitality Global
-
500
1,000
1,500
2,000
2,500
3,000
FY19
FY20	
FY21
FY22	
FY23	
FY24
FY25-FY29
 
-
500
1,000
1,500
2,000
2,500
3,000
FY19
FY20	
FY21
FY22	
FY23	
FY24
FY25-FY29
-
500
1,000
1,500
2,000
2,500
3,000
FY19
FY20	
FY21
FY22	
FY23	
FY24
FY25-FY29
-
500
1,000
1,500
2,000
2,500
3,000
FY19
FY20	
FY21
FY22	
FY23	
FY24
FY25-FY29
PAHI
capital
injection
R376m
FY19-FY24
R2.5bn
FY19-FY24
R2.7bn
FY19-FY24
R8.3bn
FY19-FY24
40%
50%
60%
70%
80%
66%
Decreasing spend on
New initiatives
0%
5%
10%
15%
20%
25%
30%
10%
% earnings on new
R0m R0m	R0m
cR500m

-- 16 of 75 --

17
Well positioned for future growth
Expect continued organic growth
Profitability
Inherent organic growth from Bank and Vitality Limited:
12.5% to 17.5%
average earnings
growth p.a.
(FY25-FY29)
20% to 30%
average earnings
growth p.a.
(FY25-FY29)
Discovery Group
Forward looking information on this slide is for illustration and has not been reviewed or reported on by the auditors

-- 17 of 75 --

18
The effect of behaviour change exceeds expectations
Physical activity has a
significant impact on mortality
and increases by age
Physical activity has a significant
impact on healthcare costs
-29%
-52%
-59%
0 (base) Low Medium High
-36% -38%
-58%
0 (base) Low Medium High
Relative mortality for the 45-65 age group
Relative mortality for the 65+ age group
Relative reduction for the 45-65 age group
Relative reduction for the 65+ age group
-16%
-25%
No Habit
Strong poor
habit
Strong good
habit
-14%
-29%
No Habit
Strong poor
habit
Strong good
habit
No
habit
Strong poor
habit
Strong good
habit
No
habit
Strong poor
habit
Strong good
habit
Effects of behaviour change increase with
age and chronicity
Young moderately
healthy 30-year-old 10.2
56.7
43.5 53.7
Healthspan Sick years
10	46.7
Middle age unhealthy
50-year-old 10
.2
16.6 24.9
Healthspan Sick years
25.1
Advanced age
unhealthy 70-year-old 4
14.6
6.1 10.1
Healthspan Sick years
11.6
+7%
increase in
healthspan
+51%
increase in
healthspan
+90%
increase in
healthspan
8.3
33.5	8.4
3

-- 18 of 75 --

19
Evolving the shared-
value model to
engage members in
a personalised
programme

-- 19 of 75 --

20
Creating two distinct businesses with
significant ambition and a common
business model
Limited

-- 20 of 75 --

21
Consolidating Vitality UK and Vitality Global to achieve two
clear composites with competitive advantage
Leading financial services group in SA via the
consistent application of the Vitality Shared-value
Insurance model, ensuring every business is a market
leader in its category and integrates with other
businesses in the Group to benefit customers; and a
best-in-class bank that enables the composite via its
unique payment systems, ecosystems and shared
currency
Leading international insurance group that
revolutionises insurance through the scaling of the
Vitality Shared-value Insurance model, utilising the UK
– and the institutional structure and strength of its
insurance businesses – as the centre of excellence and
epicentre for R&D, together with partnerships with the
best insurers globally
Ambition: Ambition:

-- 21 of 75 --

22
Discovery SA

-- 22 of 75 --

23

-- 23 of 75 --

24
Discovery Bank
Revenue
(NII + NIR)	Retail deposits Advances Operating result
Total
accounts
Total
clients
+41%
to (R454m)
+89%
to (R52m)
Before NBAC
+36% +40%
to >950k to 2.3m
+29% +27%
to R18.5bn to R6.6bn
+41%
to R2.1bn
H1
2023
H2
2023
H1
2024
H2
2024
NBAC Loss before NBAC
2020 2021 2022 2023 2024 2020 2021 2022 2023 2024 2020 2021 2022 2023 2024
Total NII Total NIR	Total Accounts Total Clients

-- 24 of 75 --

25
Strong and quality new business growth from multiple sources
Accelerating growth in sales
Relevance across
demographic groups Majority new to Discovery
1,271
-
200
400
600
800
1,000
1,200
1,400
Aug-21	
Nov-21	
Feb-22	
May-22	
Aug-22	
Nov-22	
Feb-23	
May-23	
Aug-23	
Nov-23	
Feb-24	
May-24
±1,100 sales per day
Number of other Discovery products
58% of new business is new to Discovery
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0 1 2 3 4+
0%
10%
20%
30%
40%
Credit card new business by income
#1 market share in affluent, and one of the leading
banks in mass affluent
New business by age group
High share of new business from young adults
0%
10%
20%
30%
40%
18-24 25-34 35-44 45-54 55-65 65+
SA population
3-month moving average; per business day

-- 25 of 75 --

26
Maintained focus on credit book growth and quality
1 Market average Credit Loss Ratio based on the latest results of the top 5 banks in South Africa
Strong growth in advances book
Promising home loans book and
pipeline
Better than market credit losses
driven SVM
100%
27%
12% 7% 3%
Blue Bronze Silver Gold Diamond
Credit loss ratio by VM status
0
1
2
3
4
5
6
7
Jul-22	
Aug-22	
Sep-22	
Oct-22	
Nov-22	
Dec-22	
Jan-23	
Feb-23	
Mar-23	
Apr-23	
May-23	
Jun-23	
Jul-23	
Aug-23	
Sep-23	
Oct-23	
Nov-23	
Dec-23	
Jan-24	
Feb-24	
Mar-24	
Apr-24	
May-24	
Jun-25
+27% Value of home loans disbursed, Rm	Advances, Rbn Credit loss ratio vs market1
+3.4%
96
617
17
521
149	132
New Loan Switch Total
113 653 766
Loans Disbursed Approved - legal finalisation
0%
2%
4%
6%
8%
Jun-21 Jun-22 Jun-23 Jun-24
Market average Discovery CLR TTC

-- 26 of 75 --

27
Established market leadership Best in retail banking Best in private banking
Best bank brand driven by disruptive products and superior
service
Top private banking provider
Best relationships with clients
Best service and experience metrics
Best emotional experience
Smart, simple and easy products
Excellent benefits and rewards

-- 27 of 75 --

28
Declining costs-to-serve leading to operational breakeven
Note: Jaws graph indexed to October 2023. New clients and NBAC per client graphs indexed to Q1 FY22
Positive jaws from cost
vs income
Strong operating profit
with H2 breakeven
Stable NBAC per client
as the bank grows
-600
-500
-400
-300
-200
-100
0
100
200
H1
2022
H2
2022
H1
2023
H2
2023
H1
2024
H2
2024
Loss before NBAC NBAC
H2
Breakeven
40
60
80
100
120
140
Jul-22	
Sep-22	
Nov-22	
Jan-23	
Mar-23	
May-23
Jul-23	
Sep-23	
Nov-23	
Jan-24	
Mar-24	
May-24
Cost pc Avg net income pc
Reaching breakeven
earlier than expected
Profit before NBAC, Rm
-60
-40
-20
0
20
40
60
80
100
Jul-23	
Oct-23	
Jan-24	
Apr-24	
Jul-24	
Oct-24	
Jan-25	
Apr-25	
Jul-25	
Oct-25
2023 Expectations
Current Expectations
Forward looking information on this slide is for illustration and has not been reviewed or reported on by the auditors
0
50
100
150
200
250
Q1 FY22	
Q2 FY22	
Q3 FY22	
Q4 FY22	
Q1 FY23	
Q2 FY23	
Q3 FY23	
Q4 FY23	
Q1 FY24	
Q2 FY24	
Q3 FY24	
Q4 FY24
Cumulative acquisition cost per client
New clients

-- 28 of 75 --

29
FY16
FY17
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
FY26
High quality bank with bold goals
Attributes driving growth
Capital invested, Rm
R14.5bn
(nominal)
Reducing capital needs
Projection
Capital requirements based on the Bank segmental projections
Forward looking information on this slide is for illustration and has not been reviewed or reported on by the auditors
Driven by bold ambition
R400m
operating profit
growth p.a.
Targeting
2m clients and
R3bn in profits
in FY29
1 High-quality
clients
• ±50% credit, suite and transaction
bundled
2 Deposit-led
growth
• Advances to Deposits ratio less
than 40%; deposit growth rate is
7% higher than the advances
growth rate providing a strong
funding position
• +15% above FY24 target
3 NIR-driven
income
• ±8% growth in average net
income per client from FY23 to
FY24 resulting in 45% NIR growth
4 Operational
scalability
• Cost-to-Income ratio
improvement by ±15% from FY23
to FY24
5 Optimised
profitability
• 89% growth in profit/loss before
NBAC between FY23 and FY24

-- 29 of 75 --

30

-- 30 of 75 --

31
Discovery Health
*Sasolmed contributed R2 510m to new business for FY2024
Operating profit New business Non-scheme growth	Membership
+7% +26% >3.9m
to R3 972m to R11 069m* Lives under
administration
2020 2021 2022 2023 2024 2020 2021 2022 2023 2024
>370k lives
+16%
Jan-18	
Aug-18	
Mar-19	
Oct-19
May-20	
Dec-20
Jul-21
Feb-22	
Sep-22	
Apr-23	
Nov-23	
Jun-24
Flexicare Gap Cover Healthy Company
1993
1996
1999
2002	
2005	
2008
2011
2014
2017
2020	
2023
Non Scheme Products
Restricted Schemes
DHMS

-- 31 of 75 --

32
0%
5%
10%
15%
20%
25%
30%
35%
40%
0
5
10
15
20
25
30
35
2019-20 2020-21 2021-22 2022-23 2023-24
Reserve Actual Solvency
Required Solvency
0%
2%
4%
6%
8%
10%
2019-20 2020-21 2021-22 2022-23 2023-24
0%
1%
2%
3%
2019-20 2020-21 2021-22 2022-23 2023-24
Upgrades Downgrades
Discovery Health Medical Scheme: continued excellent performance
in a complex environment
Membership and market share as at June 2024	
Plan changes exclude impact of plan closures
Membership Customer satisfaction Solvency
57.9% market share Low proportions of members change plans, with
more members upgrading than downgrading:
Lapses continue to remain stable
R28.4bn
30%
AAA
projected unaudited reserves
projected unaudited solvency
credit rating
R billion
96% no plan changes
DHMS Rest of the industry
Others

-- 32 of 75 --

33
High utilisation driving medical inflation
Overall
medical
inflation
Tariffs Supply side
utilisation
Risk mngt,
Vitality effect &
efficiencies
Demand
side
utilisation
+
4.8%
+
2.5%
Net:
7.4% to 10.9%
+
1.9% to 5.4%
–
1.8%
Increased ageing of the scheme contributes
47% to the demand side utilisation	1
Demand side utilisation ranges from 1.9% to 5.4%
depending on the plan type, with an average of 4.1%
Increasing chronicity accounts for 15% of the
demand side utilisation*	2
The buy-down effect & plan mix contributes
38% to the demand side utilisation	3
Over the last 10 years, c39% of demand
side impact is due to adverse selection
Chronic beneficiaries have grown
from 15.8% in 2008 to 33.1% in 2024
*The increasing chronicity captures the increased chronic prevalence over and above what is expected due to the increased aging

-- 33 of 75 --

34
Discovery Health actively addressing the issues of an ageing scheme and
increasing chronicity
Attracting young professionals Addressing chronicity
-13%
-16%-18%
-16%
-14%
-12%
-10%
-8%
-6%
-4%
-2%
0%
Clinical habits Physical activity habits
-16% -18%-20%
-18%
-16%
-14%
-12%
-10%
-8%
-6%
-4%
-2%
0%
Clinical habits Physical activity habits
Relative in-hospital cost reduction
moving from poor to strong habit
Relative mortality reduction moving
from poor to strong habit
Rich rewards through Vitality & Vitality Active
25% OFF
Healthy food
75% OFF
Gym membership
FULLY FUNDED
Fitness device
24 FREE VISITS
At other fitness facilities
Introducing ACTIVE SMART
Most affordable plan at R1,350 per month

-- 34 of 75 --

35
Additional tax revenue assumed by NDoH is not sustainable
NHI scenario relies on R200bn additional tax revenue
2,332
407
714
Current
private
medical
schemes
Current
funding
for
uncovered
lives
Current
NHI
proposal
Healthcare cost (ZAR)
Post	
Pre
Economic growth would enable greater
social spending
Required additional annual GDP growth over a 20-year
period
0%
2%
4%
6%
8%
10%
12%
50 100 200 300 400 500 600 700 800 900 1000
Additional GDP growth required
Additional Tax Revenue Rbn
Retail Reduction in profit margins Including efficiencies
DoH estimate
Primary care, extended
chronic, maternity, PMB
hospital
Extended
hospital+specialist
7.2%
10.4%
8.6%
R200bn
Additional funding
required per annum, as
indicated by the
National Department of
Health
31%
increase in
personal
income tax
or;
6.5%
increase in
VAT (from
15% to 21.5%)
or;
10x increase in
payroll tax
(current UIF
contributions)

-- 35 of 75 --

36
Section 33 is the pinch point to allowing private sector collaboration;
there are a number of other complex and critical areas in the act
33. Once National Health Insurance has been
fully implemented as determined by the
Minister through regulations in the
Gazette,
medical schemes may only offer
complementary cover to services not
reimbursable by the Fund.
1. Until the NHI is fully
implemented, there are no
restrictions on medical
schemes
2. When it is fully
implemented,
complementary cover may
be added – key question:
how comprehensive will
NHI be?

-- 36 of 75 --

37

-- 37 of 75 --

38
Discovery Life
Normalised
operating profit New business
Maintained leading
market share
Strong capital and
liquidity
2020 2021 2022 2023 2024
Individual Group
IFRS 17
+9%
to R4 765m
Individual life:
+11%
2020 2021 2022 2023 2024
Individual Group
SCR
coverage
Liquidity
coverage
2024	2024
183% R5 446m
1 X ILT
125%
SCR Target
+4%
to R2 942m
Individual life:
+4%
2023 2024
12 months to June 2024
27.3%27.1%

-- 38 of 75 --

39
Strong EV growth and improvement in VNB margin
Strong cashflow
generation
Improvement in
VNB margin Operating variances	Strong EV growth
Life and Invest cashflow
in excess of 35% of net of
tax normalised earnings
Jun23 Margin	
Business mix
Non-economic	
assumptions
Economic
assumptions	
Jun24 Margin
VNB margin (%)
2.54%
3.80%
19.3% IRR
Business mix	
and expenses
Jun-22
New Business
Expected unwind incl New
Business
Experience Variances
Methodology and Assumption
Changes
Total before Economic Impact
Experience Variances
Methodology and Assumption
Changes
Components below the line
Jun-23
R41 138m
R45 948m
R47 519m
Non-
economic
+15.5%
Economic
+11.7%
Jun
-24
Jun
-23
Expected unwind
Other (including dividends)
+14.3% RoEV Discovery Life Ltd variances, Rm
Mortality and morbidity
Persistency
Premium and fee income
Policy alterations
Other
Total non-economic
Economic
Total
R114m
-R40m
Largely offsetting
3.2%*
*Individual Life
5.0%*
2021 2022 2023 2024
CF before financing Financing repaid
Cashflows before financing
R1 960m
R2 260m
-R765m
-R638m
Covid impact
Net change in
financing
Impact of basis change:
R1.2bn on EV, R2.8bn on balance sheet

-- 39 of 75 --

40
% Growth
+7.1% +8.7% -7.0% = c9%
Expected
growth at
current new
business rates
Actual value generation of business under IFRS 17
1 Represented by DSY and competitor CSM balances rebased to the same starting level for comparative purposes; 2 SA Life and Invest (risk) portfolio; 3 SA Life Segment
IFRS 17 stored margin absorbs basis change2 Stable earnings growth3
New
business
Insurance
finance
income /
expense
Release
to
earnings
Variances
and
basis
changes
Other
Equal
offset to
release of
margins
-55 2,674
-474 2,061
559
New
business
Variances
and basis
changes
Release
to
earnings
CSM
23,423
RA
6,348
OCI
-5,264
24,507 23,499
2,787
2,110
-5,128
-2,061
2,784
-1,500
OCI
-3,980
CSM
20,237
RA
7,242
Economic
margin
Non
-economic
margin
June
2023
June
2024
Net impact of -
-R2.3bn
6% of PVFCF of
corresponding
business
Insurance
finance
income /
expense
Comparative non-economic margin1
runoff excl new business
Positive margin dynamics
1 2 3 4 5 6 7 8 9 10
CSM Balance (rebased)
Projection Year
Competitor 1 Competitor 2
Competitor 3 SA Life and Invest GMM
28,264
OCI
-3,980
CSM
20,237
RA
7,242
In-period
earnings
4,765
Store of value at start of period plays out as earnings during the period plus store
of value at end of period (Rm)
Total
current
and future
value

-- 40 of 75 --

41

-- 41 of 75 --

42
2020 2021 2022 2023 2024
Once-off
items
Discovery Invest
Normalised operating
profit New business
Positive shift in product
mix
Assets under
administration
+20% +8% +11%
to R1 522m to R3 300m to R155bn
2020 2021 2022 2023 2024
+12%
IFRS 17
Jan-17	
Sep-17	
May-18	
Jan-19	
Sep-19	
May-20
Jan-21	
Sep-21	
May-22	
Jan-23	
Sep-23	
May-24
% AuM in offshore funds
0%
5%
10%
15%
20%
25%
30%
35%
40%
Feb-22	
May-22	
Aug-22	
Nov-22	
Feb-23	
May-23	
Aug-23	
Nov-23	
Feb-24	
May-24
Rebased profit release profile
(guaranteed bonds)

-- 42 of 75 --

43

-- 43 of 75 --

44
Discovery Insure
1 Prior years have been restated to exclude vehicles that remain on Discovery Insure's books without cover during the Gap in Cover period
Gross written premium Gross new business
Normalised operating
profit	Vehicles insured1
+9% +11% +240%	+2%
to R5 726m to R1 388m to R248m	to 288 120
2020 2021 2022 2023 2024	2020 2021 2022 2023 2024 2020 2021 2022 2023 2024 H1
21
H2
21
H1
22
H2
22
H1
23
H2
23
H1
24
H2
24
IFRS 17

-- 44 of 75 --

45
Vitality Car Rating underpinned by rich dataset, enabling an
opportunity to disrupt the second-hand vehicle market
Driving and telematics
data linked longitudinally
Insure’s longitudinal view of a vehicle provides
richer insights than traditional cross-sectional view
Leveraging complex actuarial
modelling to measure value
Kilometres of driving data
collected since inception
20bn
Driving events detected
each day
800k
Average number of cars
going for panel beating p.a.
54k
Vehicle claims received in
FY2024
93k
General dealerships Discovery Insure
VEHICLE
DETAILS
• Vehicle make and model
• Service history in DI
• Vehicle assessment
• What the vehicle is used for
• Speeding by power-to-weight
• Region
• Cold starts
• Time spent in sun
• Distance travelled
• % of city vs highway driving
• Average trip speed
• Number of trips
• Average trip distance
• Road surface quality
• Accidents split by cosmetic,
mechanical, structural
• Repairer, repair details,
warranties on parts
• Detailed accident history:
frequency, severity,
geolocation, impact alert.
• Driving profile - speeding,
cornering, acceleration,
braking
• Speed relative to power
• Vertical oscillation
• Vehicle make and model
• Service history
• Vehicle assessment
• Distance travelled
• Severity
• Number of accidents
NO INFO
MILEAGE
TYPE
ACCIDENT
INFO
DRIVING
STYLE
Boost the vehicle
resale value by
up to 15%
8%
Discovery Insure
vehicles have a
5-star rating
Over 300 dealerships, representing over 30
brands including:

-- 45 of 75 --

46
Hyper-personalisation and shared
value with the Bank as the composite
maker

-- 46 of 75 --

47
Personal Pathways manifesting on the face of the Bank

-- 47 of 75 --

48
Vitality Limited
Vitality Limited
Vitality Health	
Vitality Life	
Vitality Network	
Vitality Health	
International

-- 48 of 75 --

49
UK

-- 49 of 75 --

50
Highly
rated
Vitality UK has strong assets and attributes that position it for
growth going forward
Excellent
service
Strong brand
Top
employer
Amongst the top ten
‘Best Places to Work:
Very Big
Organisation’s in The
Sunday Times Awards
2024
307% growth in
brand awareness,
compared to 5%
growth in market
average
Trustpilot (4.3/5) and
app store ratings
(4.9/5)
Over 1.8 million
lives
Over £1.1 billion in
premiums
Jun-24	
Jun-23	
Jun-22	
Jun-21	
Jun-20	
Jun-19	
Jun-18	
Jun-17
2019
2020
2021
2022
2023
2024
Unique brand
collaborations with
new partner, Itsu
Over £180m in new
business API
2019
2020
2021
2022
2023
2024
3rd largest health insurer
and life term and CI
writer
Well-recognised
mascot
High
engagement
250k Apple Watches;
100,000 ‘active’ gym
members; 75% have
actively registered on
our Member Zone

-- 50 of 75 --

51
Health

-- 51 of 75 --

52
VitalityHealth
1 Excludes VitalityCar write-down in prior year
Normalised operating
profit1 Earned premiums New business Lives covered
-52% +12% +10% +7%
to £18.5m to £699.3m to £105.7m to 1m
2020 2021 2022 2023 2024 2020 2021 2022 2023 2024	2020 2021 2022 2023 2024
IFRS 17
GBP millions	
GBP millions	
GBP millions
+23%
to R16.5bn
+21%
to R2.5bn
-47%
2024	2023	2022	2021	2020
to R435m

-- 52 of 75 --

53
Pressure on the NHS is driving increased utilisation and costs of
private healthcare
The Darzi Review1
1 Poor NHS performance:
Missing waiting time targets since 2015, waiting lists and times have surged
2 Concerns in quality of care:
Areas of concern i.e maternity care. Cancer survival and cardiovascular disease
mortality rates for people under 75 improvements have slowed substantially
3 NHS budget not being spent where it should be:
Too great a share in hospitals, too little in the community, and productivity is
too low
4 Low capital investment:
The NHS has been starved of capital and the capital budget was repeatedly
raided to plug holes in day-to-day spending. This has resulted in crumbling
buildings that hit productivity. On top of this, there is a shortfall of £37m of
capital investment
5 Disengaged staff:
High levels of sickness absence following pandemic. Marked reduction in
discretionary effort across all staff groups
6 Rise in bureaucratic processes:
Regulatory type organisations now employ c7000 staff/ 35 per provider trust,
having doubled in size over the past 20yrs
7 Improving the NHS will take time:
Improving health service back to peak performance will take years. Unlikely
waiting lists can be cleared and other performance standards restored in one
parliamentary term
1 Source: UK government, 2 Source: NHS Digital: Referral to Treatment Waiting Times, 3 Source: Office of National Statistics
Demand driven by NHS backlogs
COVID-19
60%
80%
100%
120%
140%
160%
180%
200%
Jun-18	
Sep-18	
Dec-18	
Mar-19	
Jun-19	
Sep-19	
Dec-19	
Mar-20	
Jun-20	
Sep-20	
Dec-20	
Mar-21	
Jun-21	
Sep-21	
Dec-21	
Mar-22	
Jun-22	
Sep-22	
Dec-22	
Mar-23	
Jun-23	
Sep-23	
Dec-23	
Mar-24	
Jun-24
NHS waiting list Authorisations per 1000
NHS waiting list2 and authorisations YoY change3
Doctor
strikes
Nurses
strike

-- 53 of 75 --

54
95%
97%
99%
101%
103%
105%
107%
109%
Jan Feb Mar Apr May Jun Jul Aug
Premium PLPM Rolling 12m average Claims PLPM
Pricing actions taken in line with market to restore margin, with
retention remaining resilient
Earned premiums expected to
offset claims
Stable lapse rates despite
premium increases
Positive retention of healthier
lives
Premiums and claims PLPM 
FY25	8%
claims overrun in
FY24
100% 96% 98%
90%
98%
2020 2021 2022 2023 2024
60%
70%
80%
90%
100%
110%
120%
Bronze Silver Gold Platinum
Lapse Rate index Invited increase index
Average
Individual and SME lapse rate (rebased) Lapse rate and invited rate increase by status

-- 54 of 75 --

55
Superior operating model positions VitalityHealth for growth
1 Source: LaingBuisson Health Cover Report 19th Edition; 2 Source: Health and Protection: Individual Private Medical Insurance Report, August 2024; 3 Source S.05 reporting within the SFCR’s published on our competitor’s websites, using latest available
full year data
3rd largest health insurer Attracting healthier lives
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Bupa AXA Health
VitalityHealth Aviva
Market share by player1 Average age of individual PMI
policyholders2
-
10
20
30
40
50
60
70
Aviva Axa VitalityHealth
Increased claims ratios expected
to stabilise
Market vs VitalityHealth claims ratios3
61%
68% 67%
73%
53%
48%
51%
54%
58%
2020 2021 2022 2023 2024
Market excluding VH VitalityHealth

-- 55 of 75 --

56
Life

-- 56 of 75 --

57
VitalityLife
Normalised operating
profit Earned premiums New business Lives covered
-27% +10% +4% +6%
to £15.9m to £401.9m to £83.1m to 810k
2020 2021 2022 2023 2024	2020 2021 2022 2023 2024	2020 2021 2022 2023 2024 2020 2021 2022 2023 2024
IFRS 17
GBP millions	
GBP millions	
GBP millions
+21%
to R9.5bn
+14%
to R2.0bn
-20%
to R375m

-- 57 of 75 --

58
Robust underlying performance, with further action taken to
manage PAC book
Strong operating results
before basis change
Low margins on the PAC
book
Actions to position PAC
book for stability
Taken action to address key
issues with the PAC and VLL
books, and expect a smoother
and stronger emergence of
profits each year going
forward
PAC book generates
substantial cash
80%
20%
VLL
PAC
10.4
318.7
14
62.6
PAC VLL
CSM RA
Policy count split between VLL
and PAC (%)
Margin balances in VLL and
PAC, £m
FY 23
profit
Profit
before
basis
changes
Basis
changes
FY 24
profit
+31%
-27%
2022 Deferred Part VII transfer
2023
Reconfigured hedging
strategy to align with
IFRS 17
2024
Significant
strengthening of basis
for level-premium WOL
business
Changes to accounting
policy to correctly reflect
nature of PAC book,
which will result in lower
period on period
volatility
0
5
10
15
20
25
30
35
40
FY 5	
FY
FY 7	
FY 8	
FY
FY 0	
FY
FY
FY
FY 4	
FY 5
PAC book net cashflow before
reserving requirements, £m
Operating profit, £m
Forward looking information on this slide is for illustration and has not been reviewed or reported on by the auditors

-- 58 of 75 --

59
Operating environment has been challenging, but changing
dynamics provide opportunities
Large, stagnant market; fundamentals improving The optimiser product has 3 unique product features
779 718 767 760 776
2019 2020 2021 2022 2023
Rich multi-benefit business is
increasingly common in the market
4th largest
life insurance
market
Market sales1, £m
Optimiser provides dynamic discounts1
Significantly higher engagement on optimiser2
Optimiser drives better actuarial dynamics -
retaining better risks and reducing claims	3
-49%
None Low Medium High
Claims by physical activity band
-47%
No Points Low Moderate High
Lapse rate by physical activity
Up to 30% lower premiums than
standard rate
3x more engaged than non-optimised
members
98%
of advisers recommend
products through portals,
leading to commoditisation+20%
2019 2023
% of sales on a multi-benefit basis2
1 GenRe Protection Pulse, 2 NMG UK Distribution Insights

-- 59 of 75 --

60
Generating new business value through price optimisation
Creates unique portal
competitive advantage
Enables higher rider
benefit take-up
Driving operational
efficiencies A ‘tale of two halves’
Improved pricing
sophistication & speed
Optimised:
Position 1
Non-Optimised:
Position 9
Portal design encourages
advisers to quote on other
life insurance benefits
Relative rider adoption
+52%
+150%
Non-
Optimised
Optimised
Optimiser customers
have significantly
higher benefit size
and rider adoption
Non-
Optimised
Optimised
Average benefit size	Utilising an optimisation
loop that is underpinned
by a rich & comprehensive
dataset, with features
unique to Vitality
Strategic Action:
Efficient Frontier
We optimise
Value
Models
Conversion
Models
70%
71%
73%
77%
Q1 Q2 Q3 Q4
STP Rate during FY24
77%
of applications are now
automatically decisioned
18% volume growth H2 on H1
+
Improved profitability mix
=
£million H1 H2 FY24
New business
APE 29.1 34.3 63.4
New business
net value -0.5 16.6 16.1
VNB (£m) -5.7 0.3 -5.5
VL was up 11% H2 FY24 on
H2 FY23
Wider UK protection
market (excl VL) was down
4.5% during the period

-- 60 of 75 --

61
Actual value generation of business under IFRS 17
1 Represented by Vitality and competitor CSM balances rebased to the same starting level for comparative purposes
IFRS 17 stored margin absorbs basis change Stable earnings growth
% Growth
Comparative non-economic margin1
runoff excl new business
Positive margin dynamics Store of value at start of period plays out as earnings during the period plus store
of value at end of period (GBPm)
1 2 3 4 5 6 7 8 9 10 11
CSM Balance (rebased)
Projection Year
Competitor 1 Competitor 2
Competitor 3 VitalityLife
= -c2.5%
expected
growth p.a.
before
variances
Economic
margin
New
business
Insurance
finance
income/
expense
Variances
and basis
changes
Release
to
earnings
Non
-economic
margin
June
2023
June
2024
CSM
366
RA
66
OCI
30
462
518
9
+4.5%
20
+2.0%
-40
-9.0%
-16
54
28
OCI
112
CSM
333
RA
73
H1: 1.5
H2: 18.3
Significantly
improved
new business
margins in
the second
half
New
business
Insurance
finance
income /
expense
Variances
and
basis
changes
Release
to
earnings
Other Total
current
and future
value
-4
10
-24
40 -6
Equal
offset to
release of
margins
OCI
112
CSM
333
RA
73
In-period
earnings
15.9
533

-- 61 of 75 --

62
Network

-- 62 of 75 --

63
2020 2021 2022 2023 2024 2020 2021 2022 2023 2024
Vitality Network
Integrated API by
insurance partners Revenue
Insurance partners
membership	Operating profit
+11%
to $1 575.1m
+18%
to R29.7bn
+10%
to $101.3m
+16%
to R1.9bn
+23%
to $28.5m
+30%
to R533m
+17%
to 5.3m
2020 2021 2022 2023 2024
USD millions	
USD millions	
USD millions
2020 2021 2022 2023 2024

-- 63 of 75 --

64
Vitality Network’s globally expanding footprint

-- 64 of 75 --

65
Key strategic focus areas
1 Grow revenue through deepening of
existing insurance partnerships and
targeted pursuit of new insurance
partnerships
2 Evolve Vitality products to drive greater
value through utilisation of the science
of hyper-personalisation
3 Unlock geared profits by significant
revenue growth (through scaling) and
maintaining a flat expense base
+10% Revenue growth
for FY2024 (USD)
+23% Profit growth for
FY2024 (USD)
19% 21% 21%
26% 25%
30%
2019 2020 2021 2022 2023 2024
Profit margin (excl. FX)
Redeveloped the mobile architecture to
support the incorporation of the habit index
and hyper-personalisation, through physical
activity and healthy actions
Hosted partner-
wide GVC, rolling
out personalisation
enhancements
Revolutionised
the mobile
experience
Expansion of
strategic role of
Vitality Stand Alone –
focus on 2030 targets
Driving VONB
growth - focus on
agent engagement

-- 65 of 75 --

66
The V1 Platform enhances Vitality Limited’s ability to expand globally
𝑞 𝑥+𝑡
𝑞 𝑥
𝑞 𝑥 | 𝑦
𝑞 𝑥+𝑡 | 𝑦
𝑞 𝑥+𝑡 𝑦 𝑧
Mortality rate
Age
Up to 31%
Reduction in
mortality*
Value generated
through
engagement and
formation of
healthy habits
Swiss Re is Discovery’s
collaboration partner
*Clinical and physical activity habits must be sustained for rest of life to
achieve this reduction in mortality
𝑥 = 𝑎𝑔𝑒
𝑦 = 𝑙𝑖𝑓𝑒𝑠𝑡𝑦𝑙𝑒 𝑎𝑛𝑑 𝑐𝑙𝑖𝑛𝑖𝑐𝑎𝑙 ℎ𝑎𝑏𝑖𝑡𝑠 𝑢𝑝 𝑡𝑜 𝑎𝑔𝑒 𝑥, 𝑎𝑛𝑑 𝑠𝑡𝑎𝑡𝑒 𝑜𝑓 ℎ𝑒𝑎𝑙𝑡ℎ 𝑎𝑡 𝑎𝑔𝑒 𝑥
𝑧 = 𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑛𝑒𝑤 𝑙𝑖𝑓𝑒𝑠𝑡𝑦𝑙𝑒 𝑎𝑛𝑑 𝑐𝑙𝑖𝑛𝑖𝑐𝑎𝑙 ℎ𝑎𝑏𝑖𝑡𝑠 𝑓𝑟𝑜𝑚 𝑎𝑔𝑒 𝑥 𝑜𝑛𝑤𝑎𝑟𝑑𝑠
QUICK
to implement 3-month deployment into new
markets
Redeployable modules
EFFICIENT
to operate Standardised process & once-off builds
to link partners, upgrade products,
enhance features across the board
EASY
to configure
Cloud based
Multi-language
Scalable

-- 66 of 75 --

67
VHI

-- 67 of 75 --

68
Vitality Health International
1
2
3 USA
Leveraged the Group's data and assets
to enhance its product offerings and
expand its market share in the US
Excellent pre-tax
operating profit growth
Expanded reach
into 6 countries
Maiden dividend
to shareholders
Taken action to ensure strong
business fundamentals
Improved operating ratio
Increased diversification
Reduced investment income volatility
5 healthcare cost-saving products
deployed in 6 Asia-Pacific markets
Major product upgrade
nearing completion
Progress in sales to US
health plans, a key
strategic segment
Products span across the entire value chain of health insurance
Vitality USA has built an
integrated digital health &
care experience
Strong operating result with reduction in
combined ratio, strong cash generation
& maiden shareholder dividend
30% of CY 2023
distributable profits
R255 million
DSY’s share after
withholding tax
Note: Quantium Health, which is part of VHI, has not been included in this update
Systems Data &
Analytics
Risk
management
Digital
engagement Other
Claims
Benefit mgmt.
Risk profile
Clinical encoder
Vitality
CDM
PMI product
Network etc.
Provider mgmt.
FWA etc.
Vitality
3.0 Regional Blue Cross Blue Shield
plan, and largest provider-
sponsored health plan in state

-- 68 of 75 --

69

-- 69 of 75 --

70
Ping An Health Insurance
PAHI’s operating
results pre-tax
Discovery’s operating
result after tax
PAHI licence new
business1	Written premium1
+56% +82% +12%	+15%
to RMB2.1bn
(RMB 0.5bn
DSY’s share)
to RMB434m to RMB3.8bn	to RMB22.6bn
Lives
+26%
to 27.4m PAHI licence
lives
+59% +85% +14%	+17%
to R5.4bn
(R .4bn DSY’s
share)
to R1 124m to R9.9bn	to R58.6bn
1 100% of PAHI
2020 2021 2022 2023 2024 2020 2021 2022 2023 2024 2020 2021 2022 2023 2024
Reinsurance
PAHI licence
2020 2021 2022 2023 2024
Jun-20	
Dec-20
Jun-21	
Dec-21	
Jun-22	
Dec-22	
Jun-23	
Dec-23	
Jun-24
RMB millions	
RMB millions	
RMB millions	
RMB millions

-- 70 of 75 --

71
Strong business fundamentals after years of focus on building a
quality specialist health insurer
Improved operating ratio
Reduced investment income
volatility Increased diversification
All figures are for the period 1 January – 30 June for the corresponding year, unless otherwise stated
• Restructured agent commissions, reducing
costs and improving tax efficiency
• Improved risk management, lowering loss
ratio;
o Strengthened claims risk management
o Enhanced underwriting
o Upgraded non-disclosure systems
• Revised investment return target for a more
conservative asset allocation
• Reduced equity exposure
• Focused on assets yielding non-taxable
returns
• Revamped SuiShenYi
• Partnered with flagship third-party brokerages
• Launched tailored products across
affordability and healthcare needs
• Targeted products for channels like Douyin,
Mingya and Ant
Combined ratio
50%
70%
90%
110%
2020 2021 2022 2023 2024 2020 2021 2022 2023 2024
Investment income
and gains
Profit before
investment income
and gains
PAHI’s operating result pre-tax
79 58
21 42
2023 2024
Non-eShengBao
eShengBao
74 71
26 29
2023 2024
Non-PAL PAL
Channels
Products
Investable assets
(RMB m, as at 30 June)
19,869 23,328
2023 2024
+17%

-- 71 of 75 --

72
Maintained robust balance sheet
1 For the period 1 January – 30 June for the corresponding year
2 As at 30 June for the corresponding year
Cashflows from
operating activities1 Retained earnings2
First dividend paid to
shareholders	Comprehensive SCR2
30% of CY 2023
distributable profits
R255 million
Discovery’s share
after withholding tax
Jun-23 Jun-24
1,949
1,778
+10%
RMB million RMB million
Jun-23 Jun-24
3,079
4,247
+38%
Jun-23 Jun-24
267%
320%
RMB3.27bn
for 12 months Jun 23 – Jul 24

-- 72 of 75 --

73
In summary
1 Strong FY24 performance
2 Entering a new phase in the
lifecycle of the Group
3
Normalised
operating profit
+17%
New
business
+18%
FLR
20%
Cash
conversion
66%
Scaling of the
Vitality Shared-
value Insurance
model
Enabling
Discovery Bank
as composite
maker for SA
Earnings
growth
15-20%
% spend
on New
c5%
Cash
conversion
60-70%
RoE
15-20%
Creating two distinct businesses
with significant ambition and a
common business model
FLR
10-20%
Dividend
<5x

-- 73 of 75 --

74
Presentation Disclaimer
This presentation has been prepared based of the Discovery Group’s reviewed
condensed consolidated financial information for the year ended 30 June 2024
and the notes to the condensed consolidated financial statements have been
reviewed by our independent joint auditors, Deloitte & Touche and KPMG Inc.
who expressed an unmodified review conclusion. The review report does not
necessarily report on all information contained in these financial results.
This presentation may contain forward looking statements with respect to certain
of Discovery’s plans and its current goals and expectations relating to its future
performance and results. All forward looking statements involve risk and
uncertainty because they relate to future events and circumstances which are
beyond Discovery’s control. Accordingly, Discovery’s actual future financial
performance and results may differ. Any reference to future financial
performance has not been audited or reported on by the Group’s auditors.

-- 74 of 75 --

Annual Results
Presentation
for the year ended 30 June 2024

-- 75 of 75 --